Home / Managing Editor, Diabetes in Control (page 130)

Managing Editor, Diabetes in Control

The Value of the Nitric Oxide Pathway and its Importance in African-American Patients with Heart Failure

Talking to Patients

Studies in heart failure and hypertension have shown that people who identify themselves as black may have a less active renin-angiotensin system and a lower bioavailability of nitric oxide. The A-HeFT study was conducted to determine if a fixed dose of isosorbide dinitrate (ISDN) and hydralazine would provide additional benefit in black patients with heart failure.

Read More »

Editor’s Note – DCMS-258

I was reading this week’s Clinical Gem about the use of diuretics for reducing heart failure and blood pressure values. There was a mention of the differences in responses among certain ethnic groups and the difficulty that we often have with African-American patients. There was a lot of focus on …

Read More »

Dragon Dictation

Dragon Dictation is an easy-to-use voice recognition application powered by Dragon® NaturallySpeaking® that allows you to easily speak and instantly see your text or email messages. In fact, it’s up to five (5) times faster than typing on the keyboard. Features: Voice-to-text transcriptions that may be sent as SMS, Email, …

Read More »

Test Your Knowledge Question #798

Test Your Knowledge

A 43-year old patient with a 2-year history of type 2 diabetes presents to your office for a follow-up visit. She is a highly motivated patient and doesn’t have any significant co-morbidities, so together, you have set a target A1C= 6.5%. Her current medications are metformin and sulfonylurea. Despite her good efforts, her current A1C is 7.3%. You would like to add a third agent to her regimen, however she is concerned about any additional weight gain as she has gained a few pounds since starting the sulfonylurea. Which drug class would you add to minimize any additional weight gain? A. Basal insulin B. GLP-1 agonist C. Thiazolidine D. DPP-4 Inhibitor Follow link to take the test!

Read More »

Imperium: World’s First Instant Insulin Patch

Unilife Corporation has launched the world’s first instant insulin patch, Imperium. Imperium is a prefilled, preassembled, multi-day wearable insulin pump for continuous subcutaneous insulin infusion and on-demand bolus delivery through the push of a button. It is equipped with Bluetooth connectivity to wirelessly connect with smartphone apps for patient reminders …

Read More »